Asset

  • No.

    101

  • Asset Title

    Targeting IL1RAP To Eradicate Leukemia Stem Cells (LSC) In Acute Myeloid Leukemia (AML)

  • Organization

    City of Hope

  • Product Type

    Antibody

  • Therapeutic Area

    Oncology

  • Development Stage

    Target Identification or Validation

  • Technical Summary

     IL1RAP is a good target for immune therapy 

    • Interleukin-1 receptor accessory protein (IL1RAP, IL1R3) is a coreceptor involved in several signaling pathways including interleukin-1 (IL-1), IL-33, IL-36G, and stem cell factor (SCF). 

    • Signaling by IL-1 requires the formation of a cell surface receptor complex involving IL-1, interleukin-1 receptor type 1 (IL1R1), and IL1RAP. Lack of IL1RAP completely abrogates cellular responses to IL1. 

    • IL1RAP is present on the cell surface of candidate chronic myeloid leukemia LSCs, AML blasts and CD34+ cells which include LSCs, and myelodysplastic syndrome, but not on normal HSC. 

    • Studies with IL1RAP-/- knockout mice indicate that IL1RAP is dispensable for normal HSC function. 

  • Patent

    WO2021030484A2

  • Publication

  • Attachment

TOP